Protocol Ledger

NCT05007080 · Phase II · COMPLETED

A Study to Evaluate Different Dose Levels of Ad26.COV2.S in Healthy Adolescents From 12 to 17 Years Inclusive

Interventional Phase II clinical trial protocol NCT05007080 sponsored by Johnson & Johnson / Janssen in Infectious Disease and Vaccines, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-09-27 Enrollment: 304 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05007080
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)304 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)1 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05007080
Protocol FieldVerified Registry Value
NCT IdentifierNCT05007080
Consolidated Lead SponsorJohnson & Johnson / Janssen
Therapeutic Condition CohortInfectious Disease and Vaccines
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment304 participants (ACTUAL)
Registered Start Date2021-09-27
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT05007080
Hospital Research SiteLocationSite Profile
Hospital Universitario "Dr. Jose Eleuterio Gonzalez"Monterrey, MexicoOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Johnson & Johnson across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Infectious Disease and Vaccines Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI